Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN ASPART

All injection strengths: general benefit

Other products in the same Health Canada class (A10A, A10AB) — coverage varies; not interchangeable

  • Insulin zinc crystalline human biosynthetic rdna origin (Humulin Regular): general benefit
  • Insulin glulisine dna origin (Apidra): general benefit
  • Insulin human biosynthetic (Novolin ge Toronto): general benefit
  • Insulin lispro (Humalog): general benefit, Limited Use 646
  • Human biosynthetic + insulin (Entuzity KwikPen): general benefit

Kirsty · DIN 02520974 · 100U/mL · injection solution-5X3mL pre-filled pen Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kirsty · DIN 02520974 Manufacturer: Bicon SDN. BHD.; listing date 2023-01-31 Health Canada: Marketed since 2026-05-07 · brand KIRSTY · ATC A10AB05 INSULIN ASPART · form Solution · route Subcutaneous · ingredients INSULIN ASPART 100 UNIT/ML · company Biocon biologics canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Kirsty: Formulary list price $42.7125/unit (unit not stated in source; not the patient's cost)

Ministry pays: $42.7125 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101021 · Verify on the e-Formulary ↗ (DIN 02520974)

Source record
DIN 02520974: Kirsty Raw flags: insOH=Y, sec3=Y Item: 682010049; group id 770; item number 1878; lccId None; manufacturer id BSB Source form: Inj Sol-5X3mL Pref Pen Pk; strength: 100U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $42.7125; ministry $42.7125 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520974 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101021
Shortage status: resolved shortage (ended 2026-06-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520974
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:10 Insulins (Rapid Acting)) and how they are covered

Matched class: 68:20:10 Insulins (Rapid Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN GLULISINE (DNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC, INSULIN INJECTION, HUMAN BIOSYNTHETIC Some products covered without a code (check the product listing): INSULIN LISPRO 68:20:10 Insulins (Rapid Acting)

INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN GLULISINE (DNA ORIGIN)

· 3 products · General benefit · strengths: 100U/mL · Inj 5x3mL Cart ClickStar Pen, Inj Sol-10mL Vial, Inj Sol-5x3mL SoloSTAR Pref Pen

INSULIN HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN LISPRO

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL, 200U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk, Inj Sol-Pref Pen 5x3mL Pk

INSULIN INJECTION, HUMAN BIOSYNTHETIC

· 1 products · General benefit · strengths: 500U/mL · Inj Sol-Pref Pen 2x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:10
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetes
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN HUMAN BIOSYNTHETIC, INSULIN LISPRO & INSULIN LISPRO PROTAMINE INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10 Product monograph INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10 Product monograph INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70% · General benefit  The treatment of adult patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00062479.PDF; date JUL 11, 2017; DIN 02265435; fetched 2026-09-10 Product monograph INSULIN HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024233; fetched 2026-09-10 Product monograph INSULIN LISPRO · Limited Use, codes 646 (1), General benefit (4) INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02229704; fetched 2026-09-10 Product monograph INSULIN LISPRO & INSULIN LISPRO PROTAMINE · General benefit INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications NOVORAPID® (insulin aspart) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. NOVORAPID® should normally be used in regimens together with an intermediate or long-acting insulin. NOVORAPID® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for insulin infusion. 1.1 Pediatrics Pediatrics (2-17 years of age): Evidence from clinical studies and experience suggests that use in the pediatric population is not associated with any differences in safety or effectiveness. Please see 10 Clinical Pharmacology. 1.2 Geriatrics Geriatrics (> 65 years of age): There was no clinically relevant difference in the pharmacokinetics and pharmacodynamics of NovoRapid® between elderly and younger subjects. Please see 7 Warnings and Precautions and 10 Clinical Pharmacology. https://pdf.hres.ca/dpd_pm/00084670.PDF PM date: 2026-05-12 Source product: NOVORAPID; DIN 02245397; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.